SCHEMBL3223591

SCHEMBL3223591

COCN(CCO)c1nc(N(COC)COC)nc(N(COC)COC)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 18/20 0.44
PRUNE1 Q86TP1 2/20 0.37
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
PDE2A O00408 1/20 0.35
RGS12 O14924 1/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
ABCC4 O15439 1/20 0.35
ABCC5 O15440 1/20 0.35
PDE6D O43924 1/20 0.35
PDE8A O60658 1/20 0.35
GMNN O75496 1/20 0.35
USP2 O75604 1/20 0.35
PDE5A O76074 1/20 0.35
ABCB11 O95342 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HSP90AA1 P07900 1/20 0.35
CHRM2 P08172 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6124092 1.00 SLC29A1 (0.44) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL436650 0.98 SLC29A1 (0.47) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL11986991 0.96 SLC29A1 (0.48) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL2754985 0.91 SLC29A1 (0.42) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL18174859 0.89 SLC29A1 (0.43) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL17857263 0.89 SLC29A1 (0.54) SLC29A1PRUNE1KDM4EMEN1PDE2A
SCHEMBL12134868 0.86 SLC29A1 (0.41) SLC29A1PRUNE1
SCHEMBL18288099 0.85 SLC29A1 (0.40) SLC29A1PRUNE1MEN1ALDH1A1GAA
SCHEMBL123963 0.84 ALDH1A1 (0.38) SLC29A1ALDH1A1LMNAMAPTTHRB
SCHEMBL18541162 0.83 SLC29A1 (0.36) SLC29A1PRUNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9482958-B2 Method of forming pattern and developer for use in the method FUJIFILM CORPORATION (JP) 2016-11-01 US disclosed
US-20150293454-A1 METHOD OF FORMING PATTERN AND DEVELOPER FOR USE IN THE METHOD FUJIFILM CORPORATION (JP) 2015-10-15 US disclosed
US-20120288691-A1 PATTERN FORMING METHOD, PATTERN, CHEMICAL AMPLIFICATION RESIST COMPOSITION AND RESIST FILM FUJIFILM CORPORATION (JP) 2012-11-15 US disclosed
US-20120282548-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM FUJIFILM CORPORATION (JP) 2012-11-08 US disclosed
US-20120148957-A1 PATTERN FORMING METHOD, CHEMICAL AMPLIFICATION RESIST COMPOSITION AND RESIST FILM FUJIFILM CORPORATION (JP) 2012-06-14 US disclosed
US-20120003591-A1 METHOD OF FORMING PATTERN AND DEVELOPER FOR USE IN THE METHOD FUJIFILM CORPORATION (JP) 2012-01-05 US disclosed
US-20080241745-A1 Mixture of alkali soluble polymer, crosslinking agent, acid generator ; radiation with actinic radiation; quaternary ammonium compound FUJIFILM CORPORATION (JP) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282548-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM RAD51, RER1, RXRA SLC29A1 2791/4885PRUNE1 1421/4885KDM4E 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.